Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 4/20 | 0.46 |
| ▸ | ACACA | Q13085 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.40 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.38 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14166208 | 0.96 | ACACB (0.45) | ACACBACACASMN1; SMN2TSHRALDH1A1 | |
| SCHEMBL18320646 | 0.87 | ALDH2 (0.45) | ACACBACACASMN1; SMN2TSHRALDH1A1 | |
| SCHEMBL27936181 | 0.81 | TSHR (0.52) | SMN1; SMN2TSHRALDH1A1TP53CYP3A4 | |
| SCHEMBL31198896 | 0.81 | RAB9A (0.50) | ALDH1A1POLBMAOBKDM4EL3MBTL1 | |
| SCHEMBL16902876 | 0.81 | TSHR (0.54) | SMN1; SMN2TSHRALDH1A1GPBAR1CYSLTR1 | |
| SCHEMBL10602833 | 0.81 | TSHR (0.54) | SMN1; SMN2TSHRALDH1A1GPBAR1CYSLTR1 | |
| SCHEMBL11941563 | 0.79 | ALDH1A1 (0.52) | ACACBACACASMN1; SMN2TSHRALDH1A1 | |
| SCHEMBL16902884 | 0.79 | TSHR (0.53) | SMN1; SMN2TSHRALDH1A1GPBAR1CYSLTR1 | |
| SCHEMBL16902887 | 0.79 | TSHR (0.53) | SMN1; SMN2TSHRALDH1A1GPBAR1CYSLTR1 | |
| SCHEMBL7254533 | 0.79 | TSHR (0.53) | SMN1; SMN2TSHRALDH1A1GPBAR1CYSLTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3303333-B1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARM SPA (IT) | 2019-11-20 | — | — | EP | disclosed |
| EP-3303333-B1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARM SPA (IT) | 2019-11-20 | — | — | EP | disclosed |
| EP-3303333-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | Chiesi Farmaceutici S.p.A. (IT) | 2018-04-11 | — | — | EP | disclosed |
| US-9662323-B2 | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity | CHIESI FARMACEUTICI S.P.A. (IT) | 2017-05-30 | — | — | US | disclosed |
| US-9662323-B2 | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity | CHIESI FARMACEUTICI S.P.A. (IT) | 2017-05-30 | — | — | US | disclosed |
| US-9662323-B2 | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity | CHIESI FARMACEUTICI S.P.A. (IT) | 2017-05-30 | — | — | US | disclosed |
| WO-2016193241-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-12-08 | — | — | WO | disclosed |
| WO-2016193241-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-12-08 | — | — | WO | disclosed |
| US-20160346271-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-12-01 | — | — | US | disclosed |
| US-20160346271-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-12-01 | — | — | US | disclosed |
| EP-2718280-B1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARMA SPA (IT) | 2015-09-16 | — | — | EP | disclosed |
| EP-2718280-B1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARMA SPA (IT) | 2015-09-16 | — | — | EP | disclosed |
| US-8877774-B2 | Compounds having muscarinic receptor antagonist and beta2 Adrenergic receptor agonist activity | CHIESI FARMACEUTICI S.P.A. (IT) | 2014-11-04 | — | — | US | disclosed |
| US-8877774-B2 | Compounds having muscarinic receptor antagonist and beta2 Adrenergic receptor agonist activity | CHIESI FARMACEUTICI S.P.A. (IT) | 2014-11-04 | — | — | US | disclosed |
| US-8877774-B2 | Compounds having muscarinic receptor antagonist and beta2 Adrenergic receptor agonist activity | CHIESI FARMACEUTICI S.P.A. (IT) | 2014-11-04 | — | — | US | disclosed |
| EP-2718280-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | Chiesi Farmaceutici S.p.A. (IT) | 2014-04-16 | — | — | EP | disclosed |
| US-20130045169-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARMACEUTICI S.P.A. (IT) | 2013-02-21 | — | — | US | disclosed |
| US-20130045169-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARMACEUTICI S.P.A. (IT) | 2013-02-21 | — | — | US | disclosed |
| WO-2012168359-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARMACEUTICI S.P.A. (IT) | 2012-12-13 | — | — | WO | disclosed |
| WO-2012168359-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARMACEUTICI S.P.A. (IT) | 2012-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130045169-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | ADRB2, ADRB1, ADRA2B | ACACB 2410/4885ACACA 2460/4885SMN1; SMN2 2479/4885 |
| US-20160346271-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | ADRB2, ADRB1, ADRA2A | ACACB 2556/4885ACACA 2473/4885SMN1; SMN2 2035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.